The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
Head and Neck Cancer
HEAD AND NECK CANCER ADVISOR
FEATURED CONTENT
-
-
How Durable Are Responses to Targeted Therapies Across Single-Arm Cancer Trials?
Drugs approved based on changes to surrogate biomarker levels may be subject to measurement bias, according to investigators. -
Reporting Mechanisms for Conflict of Interest Disclosures in Medicine Need Standardization
ASCO officials examined the discrepancies in financial disclosures across platforms and call for a simplified system. -
Popular Genetic Tests Miss Many Cancer-Associated Genetic Variants, Particularly in Ethnic Minorities
The chance of missing a disease-causing variant can be as high as 100% across some groups. -
When Patient-Reported Outcomes Could Pose Risks
During a recent conference on quality of life in patients with cancer, FDA-affiliated researchers debunked a notion about biases — but raised some concerns about PROs.
HEAD AND NECK CANCER NEWS
Endoscopic Approaches Feasible in Surgery for Sinonasal Cancer
Pembrolizumab Prolongs Survival in Advanced Head, Neck Cancer
Delaying Treatment Worsens Head, Neck Cancer Outcomes
Adjuvant Radiation Therapy Improved Outcomes for Some With Advanced Head and Neck CSCC
Toxicity Similar, But Overall Survival Poor in Cetuximab vs Cisplatin for HPV-Positive Oropharyngeal Cancer
Want to read more?
Please login or register first to view this content.
Next post in Head and Neck Cancer
